Clinical trial
A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Adults With Type 1 Diabetes
NCT02038764 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Adults With Type 1 Diabetes
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 4, 2014
- Completion date
- September 13, 2016
- Enrollment
- 37 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.